Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Follicular Lymphoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1